Simian adenoviruses as vaccine vectors. (September 2016)

• Record Type: Journal Article
• Authors: Morris, Susan J; Sebastian, Sarah; Spencer, Alexandra J; Gilbert, Sarah C
• Is Part Of: Future virology. Volume 11:Number 9(2016)
• Page Start: 649
• Page End: 659
• Publication Date: 2016-09
• Subjects: BAC recombineering -- chimpanzee adenoviruses -- clinical trials -- simian adenoviruses -- vector vaccine; Virology -- Periodicals; Virus diseases -- Treatment -- Periodicals; 616.9101
• DOI: 10.2217/fvl-2016-0070
• Languages: English
• ISSNs: 1746-0794

Abstract

Replication incompetent human adenovirus serotype 5 (HAdV-C5) has been extensively used as a delivery vehicle for gene therapy proteins and infectious disease antigens. These vectors infect replicating and nonreplicating cells, have a broad tissue tropism, elicit high immune responses and are easily purified to high titers. However, the utility of HAdV-C5 vectors as potential vaccines is limited due to pre-existing immunity within the human population that significantly reduces the immunogenicity of HAdV-C5 vaccines. In recent years, adenovirus vaccine development has focused on simian-derived adenoviral vectors, which have the desirable vector characteristics of HAdV-C5 but with negligible seroprevalence in the human population. Here, we discuss recent advances in simian adenovirus vaccine vector development and evaluate current research specifically focusing on clinical trial data.